Normalization of Lactulose Breath Testing Correlates With Symptom Improvement in Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo-Controlled Study

  title={Normalization of Lactulose Breath Testing Correlates With Symptom Improvement in Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo-Controlled Study},
  author={Mark Pimentel and Evelyn J. Chow and Henry C. Lin},
  journal={American Journal of Gastroenterology},
OBJECTIVE:We have recently found an association between abnormal lactulose breath test (LBT) findings and irritable bowel syndrome (IBS). The current study was designed to test the effect of antibiotic treatment for IBS in a double-blind fashion.METHODS:Consecutive IBS subjects underwent an LBT with the results blinded. All subjects were subsequently randomized into two treatment groups (neomycin or placebo). The prevalence of abnormal LBT was compared with a gender-matched control group. Seven… 

Figures and Tables from this paper

Neomycin Improves Constipation-Predominant Irritable Bowel Syndrome in a Fashion That Is Dependent on the Presence of Methane Gas: Subanalysis of a Double-Blind Randomized Controlled Study

Treatment with neomycin improves constipation in C-IBS, and depends on the presence and elimination of methane on breath test, which is associated with improvement in constipation.

Lactulose Breath Testing Does Not Discriminate Patients With Irritable Bowel Syndrome From Healthy Controls

The majority of patients with IBS and healthy subjects meet criteria for an “abnormal” LBT using previously published test criteria, and groups are not discriminated using this diagnostic method, and the utility of LBT, in its current form as a diagnostic tool in IBS requires critical reappraisal.

Double-blind, Placebo-controlled Antibiotic Treatment Study of Small Intestinal Bacterial Overgrowth in Children With Chronic Abdominal Pain

Similar to adults with IBS, the prevalence of abnormal LBT suggesting SIBO in children with CAP is high; however, treatment with 10 days of rifaximin has low efficacy in normalizing LBT in this group, and additional studies are needed to determine whether a treatment approach with higher efficacy would lead to improvement.

Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome

Rifaximin was not effective in improving IBS symptoms and QOL in GW Veterans with non-constipated IBS and normalization of SIBO by LHBT was not different between rifaxim in- and placebo-treated Veterans.

Breath testing to evaluate lactose intolerance in irritable bowel syndrome correlates with lactulose testing and may not reflect true lactose malabsorption

Lactose breath testing in IBS subjects does not seem to reflect malabsorption; it may be an indicator of abnormal lactulose breath test, suggesting bacterial overgrowth.

Gut Flora and the Irritable Bowel Syndrome

It is suggested that controlled studies using culture of small intestinal aspirate as the diagnostic modality, rather than the LBHT, should be performed to further investigate the possible role of SIBO in the pathogenesis of IBS.

Comparison of Lactulose and Glucose Breath Test for Diagnosis of Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome

LBT is not a good test to discriminate SIBO in IBS patients from controls, and using GBT as gold standard for SIBO is recommended.

A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing

In contrast with IBS, the degree of abnormality on breath test is greater in subjects with fibromyalgia and correlates with somatic pain, which is not dependent on the higher prevalence of an abnormal breath test.

Comparison of Metronidazole and Placebo in Control of Gaseous Symptoms: in Patients with Functional Bowel Disorders; A Randomized Double- blind Controlled Study

This study showed no difference between placebo and metronidazole in relief of bloating and other related complaints in patients with functional bowel disease.

A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence

Rifaximin is a safe and effective treatment for abdominal bloating and flatulence, including in IBS patients, and symptom improvement correlates with reduction in H2-breath excretion.



Abnormal colonic fermentation in irritable bowel syndrome

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

An improvement in irritable bowel syndrome symptoms with diarrhea and abdominal pain being statistically significant after Bonferroni correction is revealed.

Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called 'chronic amebiasis'.

Metronidazole provides symptom relief in irritable bowel syndrome, without affecting rectosigmoid motility, and may be misinterpreted as supporting a diagnosis of 'chronic amebiasis'.

[Lactulose hydrogen breath test in small intestinal bacterial overgrowth].

The results show that the LHBT is a simple, non-invasive and relatively reliable method for diagnosis of small intestinal bacterial overgrowth.

The lactulose hydrogen breath test as a diagnostic test for small-bowel bacterial overgrowth.

The lactulose hydrogen breath test is a simple and promising diagnostic test for the detection of small-bowel bacterial overgrowth and, unlike the 14C-glycocholate test, has the advantage of being able to distinguish bacterial over growth from ileal disease.

Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns.

The results indicate that irritable bowel syndrome should be considered a disease of the small intestine as well as the colon.

A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease.

It is concluded that a detailed history, physical examination, and basic laboratory tests are sufficient in most patients for the positive diagnosis of irritable bowel syndrome and the exclusion of any underlying organic diseases.

Breath hydrogen testing in bacterial overgrowth of the small intestine.